|[July 18, 2014]
INVESTOR ALERT: Class Action Lawsuit Against Prosensa Holding N.V. Filed By Glancy Binkow & Goldberg LLP
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP, representing investors of Prosensa
Holding N.V. ("Prosensa" or the "Company") (NASDAQ:RNA), has filed a
class action lawsuit in the United States District Court for the
Southern District of New York on behalf of a class (the "Class")
comprising all persons and/or entities who purchased or otherwise
acquired the ordinary shares of Prosensa pursuant and/or traceable to
the Registration Statement and Prospectus (collectively, the
"Registration Statement") issued in connection with the Company's
initial public offering ("IPO") on or about June 28, 2013.
Please contact us at (310) 201-9150, or at email@example.com
to discuss this matter. If you inquire by email, please include your
mailing address, telephone number and number of shares purchased.
Prosensa is a biotechnology company engaged in the discovery and
development of RNA-modulating therapeutics for the treatment of genetic
disorders. The Company's first and lead product candidate was
drisapersen, which Prosensa was developing in collaboration with
GlaxoSmithKline to address a variety of mutations resulting in
inadequate production of dystrophin - a protein necessary for muscle
function. The Complaint
alleges that the Registration Statement contained materially false
and/or misleading statements and/or omitted material information
concerning the development status of drisapersen, the drug's Phase II
and Phase III clinical studies, and the prospects for drisapersen's
On September 20, 2013, less than three months after the IPO, the Company
issued a joint press release with GlaxoSmithKline, disclosing that
drisapersen had not met the primary endpoint in the Phase III study.
According to the press release, "[t]here was no treatment difference in
key secondary assessments of motor function: 10-meter walk/run test,
4-stair climb and North Star Ambulatory Assessment."
As a result of this news, Prosensa stock declined approximately 70
percent, or $16.86 per share, on unusually heavy trading volume, to
close on September 20, 2013 at $7.14 per share.
If you are a member of the Class described above, you may move the Court
no later than 60 days from the date of this Notice to serve as lead
plaintiff, if you meet certain legal requirements. To be a member of the
Class you need not take any action at this time; you may retain counsel
of your choice or take no action and remain an absent member of the
Class. If you wish to learn
more about this action, or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP,
1925 Century Park East, Suite 2100, Los Angeles, California 90067, at
(646) 539-8980, by e-mail to firstname.lastname@example.org,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To TMCnet.com's Homepage ]